Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.60 |
| ▸ | TAS1R3 | Q7RTX0 | 12/20 | 0.56 |
| ▸ | TAS1R1 | Q7RTX1 | 11/20 | 0.56 |
| ▸ | TAS1R2 | Q8TE23 | 9/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MLYCD | O95822 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23573250 | 1.00 | EPHX1 (0.60) | EPHX1TAS1R3TAS1R1TAS1R2USP2 | |
| SCHEMBL11085321 | 1.00 | EPHX1 (0.60) | EPHX1TAS1R3TAS1R1TAS1R2USP2 | |
| SCHEMBL23573438 | 1.00 | EPHX1 (0.60) | EPHX1TAS1R3TAS1R1TAS1R2USP2 | |
| SCHEMBL23573460 | 0.95 | EPHX1 (0.55) | EPHX1TAS1R3TAS1R1TAS1R2USP2 | |
| SCHEMBL22287179 | 0.95 | EPHX1 (0.55) | EPHX1TAS1R3TAS1R1TAS1R2USP2 | |
| SCHEMBL16648601 | 0.84 | EPHX1 (0.81) | EPHX1TAS1R3TAS1R1TAS1R2USP2 | |
| SCHEMBL8388655 | 0.83 | EPHX1 (0.42) | EPHX1TAS1R3TAS1R1TAS1R2USP2 | |
| SCHEMBL20959559 | 0.83 | EPHX1 (0.42) | EPHX1TAS1R3TAS1R1TAS1R2USP2 | |
| SCHEMBL16204597 | 0.82 | EPHX1 (0.60) | EPHX1TAS1R3TAS1R1TAS1R2USP2 | |
| SCHEMBL13649856 | 0.82 | EPHX1 (0.60) | EPHX1TAS1R3TAS1R1TAS1R2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | ENTPD5, ADORA2A, ENTPD1 | EPHX1 629/4885TAS1R3 3215/4885TAS1R1 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.